Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Unable to recruit additional subjects due to disease rarity
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to collect whole blood from patients diagnosed with Glycogen storage disease type 1B, which will be used to support the investigation of potential therapies that address the genetic basis of this disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GSD1b G339C Homozygous (n=3) |
| ||
| GSD1b L348FS Homozygous (n=3) |
| ||
| GSD1b G339C/ L348FS Heterozygous (n=3) |
| ||
| GSD1b Parents (n=6) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Specimen Donation | Diagnostic Test | blood donation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Bipspecimen collection from subjects that are diagnosed with Glycogen Storage Disease Type Ib (GSD1b, von Gierke disease); Subjects that are the biological parent of subjects diagnosed with Glycogen Storage Disease Type Ib (GSD1b, von Gierke disease) | Bipspecimen collection from subjects or their parental guardians that are diagnosed with Glycogen Storage Disease Type Ib(GSD1b, von Gierke disease) for the purpose to analyze the biospecimens to support the investigation of potential therapies that address the genetic basis of this disease. The primary outcome measure is the collection of biospecimens for quantitative analysis using PBMC processes to report cell viability of at least 5M cells per vial. | 1 Year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
participants diagnosed with Glycogen storage disease type 1
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sanguine BioSciences, Inc. | Woburn | Massachusetts | 01801 | United States |
Not provided
| ID | Term |
|---|---|
| C562594 | Glycogen Storage Disease IB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided